Radiopharm Theranostics Limited (RADX)
RADXStock
$0.7600
-0.0200 (-2.56%) today
Last price, Nov 13, 4:00 PM ET
- Market cap
- –
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- –
- Average volume
- –
- Previous close
- $0.7800
Earnings
Next report
Financials
| Quarter | Jun 2022 |
|---|---|
| Revenue | – |
| Gross profit | – |
| Operating income | -$14.46m |
| Net income | -$20.92m |
News
8 latest- Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67Fintel · 6 days ago
- Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain Metastases RTTNews · Nov 4, 2026
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeZacks · Oct 20, 2026
- Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 17.42% to $15.81Fintel · Oct 2, 2026
- Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up RTTNews · Sep 14, 2026
- Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer RTTNews · Sep 9, 2026
- Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial RTTNews · Aug 26, 2026
- Radiopharm Advances RAD202 Phase 1 Trial To Higher 180mCi Dose Level RTTNews · Aug 20, 2026
The company
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases.
- Region
- Australia and South Pacific
- Website
- radiopharmtheranostics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.